Diabetic Gastroparesis Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

Read more about this report - Request a Free Sample

Diabetic Gastroparesis Market Overview

Diabetic gastroparesis is gaining attention as a significant complication associated with diabetes, driven by increasing disease burden and growing awareness of gastrointestinal complications. Advances in diagnosis and treatment are supporting earlier intervention, while ongoing research is expanding therapeutic options for affected patients. The market is experiencing steady growth, supported by rising diabetes prevalence, increasing demand for effective symptom management, and advancements in pharmacological and surgical approaches. The market is poised to reach USD 5.65 Billion by 2035. Greater clinical awareness and investments in innovative therapies are further strengthening market opportunities.

Diabetic Gastroparesis Market Growth Analysis and Key Influencers

Diabetic Gastroparesis Market Dynamics

The following section outlines the key factors influencing the growth of the market, including major drivers, restraints, and emerging opportunities.

Diabetic Gastroparesis Market Growth Drivers

Expanding Availability of Targeted Therapies Supports Market Landscape

Increasing availability of pharmacological treatments for diabetic gastroparesis is supporting market expansion by improving access to symptom-management options. Metoclopramide remains an important therapeutic approach for relieving symptoms associated with diabetic gastric stasis. For instance, in September 2024, Avenacy launched Metoclopramide Injection, USP in the United States as an FDA-approved therapeutic generic equivalent for Reglan. The product was indicated for acute and recurrent diabetic gastric stasis and recorded approximately USD 12.7 million in US sales for the twelve months ending June 2023. Continued availability of such therapies is expected to strengthen market growth.

Diabetic Gastroparesis Market Restraints

Safety Concerns Associated with Long-Term Therapy May Limit Market Expansion

Safety concerns associated with commonly used pharmacological treatments can limit treatment adoption and constrain market expansion. The risk of adverse effects, particularly with prolonged use of certain prokinetic therapies, can influence prescribing decisions and require careful patient monitoring. These concerns may also encourage physicians to limit treatment duration or consider alternative approaches when managing persistent symptoms. Consequently, the need to balance symptom relief with treatment safety can create challenges for sustained market growth.

Diabetic Gastroparesis Market Opportunities

Advancing Novel Prokinetic Therapies Could Accelerate Market Value

Development of safer and potentially longer-term pharmacological therapies presents significant potential for market expansion by addressing unmet treatment needs in diabetic gastroparesis. For instance, in September 2025, CinDome Pharma announced completion of enrollment in the Phase 2 envision3D trial evaluating deudomperidone in approximately 400 adults with diabetic gastroparesis, with topline results anticipated in early 2026. The program is being developed as a potential long-term treatment option, highlighting continued innovation in the therapeutic pipeline. Such advances could broaden treatment choices and support future market growth.

Diabetic Gastroparesis Market Trends

The market is witnessing several trends including the development of novel prokinetic therapies, improved symptom management, and greater focus on long-term treatment options.

Rising Development of Novel Prokinetic Therapies Is Likely to Elevate Market Growth

The development of innovative prokinetic therapies is emerging as a notable market trend, particularly for addressing persistent symptoms and unmet treatment needs. For instance, in May 2026, Dr. Falk Pharma and Renexxion reported positive Phase 2b MOVE-IT results for naronapride, with statistically significant symptom improvements at 20 mg and 40 mg doses and favorable safety and tolerability. Continued clinical advancement of such therapies is expected to expand treatment options and support market growth.

Diabetic Gastroparesis Market Share

Drug-Based Treatment Type Segment Is Positioned to Lead Market Growth

The market is segmented by treatment type into drugs and surgical treatment products. Among these, drugs are expected to lead the market due to their established role in managing symptoms and their broader applicability compared with surgical interventions. For instance, in September 2024, Avenacy launched Metoclopramide Injection, USP in the United States, which was indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The availability of injectable pharmacological treatment reinforces the continued clinical use of drugs, supporting their expected leading position and overall market growth.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Read more about this report - Request a Free Sample

Diabetic Gastroparesis Market Analysis by Region

The regions included in the report are the United States, United Kingdom, Germany, France, Italy, Spain, Japan, and India. Among these, the United States is expected to lead the market, supported by a substantial diabetic population, established diagnostic infrastructure, and increasing recognition of gastroparesis. According to Jennifer Dimino et al., 2025, United States estimates indicate gastroparesis prevalence ranging from 6.3 to 17.2 cases per 100,000 person-years, while up to 12% of patients with diabetes experience symptoms consistent with gastroparesis. The substantial patient population and treatment needs are expected to sustain market growth in the United States.

Leading Players in the Diabetic Gastroparesis Market

Diabetic Gastroparesis Market Segmentation

Key Questions Answered in the Diabetic Gastroparesis Market Report

• What was the diabetic gastroparesis market value in 2025?
• What is the diabetic gastroparesis market forecast outlook for 2026-2035?
• What are the major factors aiding the diabetic gastroparesis market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major diabetic gastroparesis market trends?
• Which product type is expected to dominate the market segment?
• Which disease type is projected to lead the market segment?
• Which procedure is anticipated to drive the market segment?
• Which end user is likely to dominate the market segment?
• Who are the key players involved in the diabetic gastroparesis market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Research Methodology

This report is developed using a robust mixed-methods research approach combining primary and secondary research, quantitative analysis, and expert validation:

• Primary Research: In-depth interviews and consultations with gastroenterologists, endocrinologists, diabetes specialists, clinical researchers, treatment decision-makers, and payer representatives across the United States, United Kingdom, Germany, France, Italy, Spain, Japan, and India.
• Secondary Research: Peer-reviewed clinical literature, treatment guidelines, epidemiological publications, regulatory information from the US FDA, EU EMA, Japan PMDA, and India CDSCO, clinical trial records from ClinicalTrials.gov, and disease and diabetes data from organizations such as the CDC, NIH, and WHO. Company disclosures, product information, and clinical development updates are also reviewed.
• Validation: Market and epidemiological estimates are triangulated through top-down and bottom-up modeling, cross-checked against published evidence, clinical trial data, regulatory records, and expert feedback.